Company Overview

RNA as of 4:00 PM ET on 12/19/14
Price
18.78
Change
0.00
Day High
18.84
Day Low
18.65
20 minute delayed data provided by eSignal
Stock price graph
     

Prosensa is a biopharmaceutical company focused on the discovery, development and commercialization of RNA modulating therapeutics. The company targets genetic disorders with a large unmet medical need, with a primary focus on neuromuscular and neurodegenerative disorders such as Duchenne Muscular Dystrophy (DMD)Myotonic Dystrophy (DM1) and Huntington's Disease (HD).

Prosensa's portfolio of clinical and pre-clinical RNA-based drug candidates is currently focused on the treatment of DMD, with 6 programs currently in development. Prosensa’s lead candidate for the treatment of DMD, drisapersen, has completed Phase III clinical trials. 

Prosensa commenced operations in 2002 and is located in Leiden, The Netherlands. The company works closely together with academia, patient groups and experts worldwide. 

View all »   RSSRecent Releases

Dec 8, 2014
Prosensa Wins Scrip 'Biotech Company of the Year' 2014 Award

Nov 24, 2014
BioMarin and Prosensa Holding N.V. Reach Agreement on Intended Public Offer for 100% of Prosensa's Outstanding Stock; Will Add Duchenne Muscular Dystrophy Products to Rare-Disease Portfolio

View all »Events & Presentations

Jan 13, 2015 at 2:00 PM CET
Prosensa Extraordinary General Meeting of Shareholders